Mission Statement, Vision, & Core Values (2024) of Aquestive Therapeutics, Inc. (AQST)

An Overview of Aquestive Therapeutics, Inc. (AQST)

General Summary of the Company

Aquestive Therapeutics, Inc. (AQST) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for patients with unmet medical needs. Founded in 2008, the company has established itself as a leader in the field of drug delivery systems, particularly through its proprietary technologies for oral films and other formulations. Its key products include Suboxone, Exservan, and Libervant, which address conditions such as opioid dependence, amyotrophic lateral sclerosis (ALS), and seizure clusters in pediatric patients, respectively.

As of 2024, Aquestive's product portfolio has generated significant revenues, with total revenues reaching approximately $45.7 million for the nine months ended September 30, 2024, reflecting a 22% increase compared to the previous year.

Company's Financial Performance in the Latest Financial Reports

In the latest financial report for the nine months ended September 30, 2024, Aquestive reported total revenues of $45.7 million, up from $37.4 million in the same period of 2023. The revenue breakdown is as follows:

The increase in total revenues was primarily driven by a substantial rise in license and royalty revenue due to the one-time recognition of deferred revenues from terminated licensing agreements. In contrast, manufacture and supply revenue experienced an 11% decline, largely attributed to decreased sales of Suboxone and Sympazan.

Introduction to Company as One of the Leaders in the Industry

Aquestive Therapeutics stands out as a leader in the specialty pharmaceutical industry, particularly due to its innovative drug delivery technologies and a strong commitment to addressing unmet medical needs. The company has carved out a niche in the market with its proprietary formulations and strategic partnerships, enabling it to maintain a competitive edge. As of September 30, 2024, the company had cash and cash equivalents of $77.9 million, providing a solid financial foundation for future growth.

Moreover, Aquestive's ongoing clinical programs and product launches reinforce its position as a forward-thinking company poised for continued success. The strategic focus on high-demand therapeutic areas, combined with robust financial performance, positions Aquestive Therapeutics as a key player in the evolving landscape of specialty pharmaceuticals.

Mission Statement of Aquestive Therapeutics, Inc. (AQST)

Mission Statement Overview

Aquestive Therapeutics, Inc. (AQST) is committed to advancing medicines that enhance the quality of life for patients through innovative delivery technologies. Their mission emphasizes a dedication to developing pharmaceutical products that deliver complex molecules through non-invasive alternatives to standard care therapies. The significance of this mission lies in its ability to guide the company's long-term goals, ensuring a focus on patient-centric solutions and the continuous improvement of therapeutic options for various medical conditions.

Core Component 1: Patient-Centric Innovation

At the heart of Aquestive's mission is the core component of patient-centric innovation. The company aims to develop medications that address specific patient needs, particularly for those suffering from conditions that require alternative delivery methods.

• Example: Libervant® (diazepam) Buccal Film, launched in April 2024, targets the treatment of seizure clusters in young epilepsy patients aged 2 to 5 years. This product represents a significant advancement over traditional administration methods, offering a non-invasive solution for acute seizure management.
• In the nine months ended September 30, 2024, Aquestive reported revenues of $45.7 million, a substantial increase from $37.4 million during the same period in 2023, reflecting the growing acceptance and demand for their patient-centered products.

Core Component 2: Commitment to Quality

Aquestive Therapeutics emphasizes a strong commitment to quality in its product development and manufacturing processes. This commitment is crucial for ensuring that the therapeutic products meet the highest safety and efficacy standards.

• Example: The company has produced over 2.7 billion doses of Suboxone® since its launch, maintaining a market share of approximately 28% in the sublingual film segment for opioid dependence treatment.
• Research and development expenses for the nine months ended September 30, 2024, reached $15.4 million, a 50% increase compared to $10.2 million in the previous year, underscoring their investment in high-quality product development.

Core Component 3: Collaborative Partnerships

The third core component of Aquestive's mission is fostering collaborative partnerships with other pharmaceutical companies. These partnerships are essential for accelerating the development and commercialization of innovative therapies.

• Example: The licensing agreement with Zambon for Exservan® demonstrates Aquestive's strategy to leverage partnerships for market access in Europe, enhancing their product offerings in the ALS treatment space.
• As of September 30, 2024, the company reported a net cash increase of $54 million, primarily from financing activities, indicating strong support from investors for their collaborative initiatives.

Vision Statement of Aquestive Therapeutics, Inc. (AQST)

Vision Statement of Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. aims to transform the way patients access and benefit from medications through innovative formulations and delivery methods. The company's vision for 2024 focuses on addressing unmet medical needs, particularly in the areas of epilepsy and severe allergic reactions, while leveraging its proprietary technologies.

Aquestive's commitment to innovation is reflected in its continuous investment in research and development. In the nine months ended September 30, 2024, the company reported research and development expenses of $15.4 million, a significant increase from $10.2 million in the same period of the previous year. This investment underscores the company's drive to enhance its product pipeline and improve patient outcomes.

The company's vision emphasizes a patient-centric approach, particularly through its flagship product, Libervant, which is designed for the treatment of seizure clusters in young children with epilepsy. Launched in April 2024, Libervant is a buccal film formulation of diazepam, which provides a non-invasive alternative to traditional delivery methods. As of September 30, 2024, Aquestive's product portfolio generated revenues of $45.7 million, up from $37.4 million in the previous year, reflecting the growing acceptance of its innovative therapies.

Aquestive recognizes the importance of strategic partnerships in achieving its vision. The company collaborates with various pharmaceutical firms to bring new molecules to market using its proprietary PharmFilm technology. These collaborations not only enhance the company’s product offerings but also expand its market reach. Notably, in 2023, Aquestive entered a licensing agreement with Zambon for the commercialization of Exservan in the European Union, which has the potential to significantly increase its market presence in the CNS therapeutic area.

As of September 30, 2024, Aquestive reported a net loss of $27.1 million, compared to a net income of $0.2 million in the same period of 2023. Despite this, the company’s cash and cash equivalents stood at $77.9 million, providing a solid foundation for future growth. The increase in financing activities, which provided net cash of $83.4 million for the nine months ended September 30, 2024, indicates strong investor confidence in the company’s vision and strategic direction.

Aquestive aims to expand its market presence by addressing the growing demand for effective treatments for severe allergic reactions. The upcoming product Anaphylm, an epinephrine prodrug, is positioned to fill a critical gap in emergency care for anaphylaxis. The company plans to submit a New Drug Application (NDA) in 2025, targeting a launch in 2026, which could significantly enhance its product lineup and market share in the allergy treatment sector.

The vision of Aquestive Therapeutics, Inc. as of 2024 is to lead in innovative pharmaceutical solutions that enhance patient care. Through a focus on research, partnerships, and the development of groundbreaking therapies, the company is poised to make a significant impact on the healthcare landscape.

Core Values of Aquestive Therapeutics, Inc. (AQST)

Integrity

The core value of integrity at Aquestive Therapeutics, Inc. emphasizes the importance of ethical conduct and transparency in all operations. This commitment is reflected in the company's approach to regulatory compliance and corporate governance.

In 2024, Aquestive has maintained rigorous adherence to FDA regulations, ensuring that all product claims are substantiated by clinical data. For example, the company submitted a comprehensive New Drug Application (NDA) for its product, Anaphylm™, demonstrating its commitment to ethical marketing practices.

Innovation

Innovation is central to Aquestive's mission to deliver advanced pharmaceutical solutions. The company's focus on developing unique drug delivery systems has led to significant advancements in treatment options.

As of September 30, 2024, Aquestive reported progress with its product pipeline, including the launch of Libervant® for treating seizure clusters in children aged two to five. This innovative buccal film formulation reflects the company's dedication to providing alternative therapies that enhance patient quality of life.

Collaboration

Collaboration is a core value that drives Aquestive's partnerships with other pharmaceutical companies and healthcare providers. These relationships are vital for advancing their product development and market reach.

In 2024, Aquestive established several key collaborations, including a licensing agreement with Zambon for Exservan®, which is aimed at ALS patients in the EU. This partnership not only expands the product's market presence but also underscores the importance of collaborative efforts in achieving shared healthcare goals.

Patient-Centricity

Patient-centricity focuses on placing patient needs at the forefront of business operations. This value drives the company to develop and deliver products that effectively address unmet medical needs.

As demonstrated in its clinical studies, Anaphylm™ has shown rapid symptom resolution in allergy patients, with a median time of twelve minutes to complete symptom resolution following administration. Such outcomes highlight the company's commitment to enhancing patient experiences and health outcomes.

Excellence

Excellence is a value that drives Aquestive to achieve high standards in all aspects of its operations, from research and development to customer service.

In the nine months ended September 30, 2024, the company reported revenues of $45.7 million from its licensed product portfolio, reflecting its operational excellence and effective business strategies. The commitment to excellence is also evident in the company's consistent investment in research and development, which totaled $15.4 million during the same period.

Updated on 16 Nov 2024

Resources:

1. Aquestive Therapeutics, Inc. (AQST) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Aquestive Therapeutics, Inc. (AQST)' financial performance, including balance sheets, income statements, and cash flow statements.
2. SEC Filings – View Aquestive Therapeutics, Inc. (AQST)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.